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Introduction {#sec001}
============

*Vibrio vulnificus* is a halophilic, estuarine bacterium that causes fatal septicemia and necrotic wound infections \[[@pone.0167699.ref001], [@pone.0167699.ref002]\]. *V*. *vulnificus* infection exhibits a broad pathogenic spectrum, a fulminating course, and a high mortality rate (\> 50%) with death occurring within days \[[@pone.0167699.ref003]\]. Thus, this pathogen represents a good model organism for the study of bacterial septicemia. Global warming appears to be contributing to the current worldwide increase in the frequency and geographical extent of *Vibrio* infections \[[@pone.0167699.ref004]\]. Previously, we have reported that the major virulence factor of *V*. *vulnificus* is repeats-in-toxin A1 (RtxA1), which induces the programmed necrotic death of host cells \[[@pone.0167699.ref005]--[@pone.0167699.ref007]\]. To identify compounds with protective activity against *V*. *vulnificus* infection, we conducted a screen of various natural products \[[@pone.0167699.ref003], [@pone.0167699.ref008]\] and found that resveratrol reduces *V*. *vulnificus* pathogenesis by interfering with its adhesion to host cells and inhibiting the production of RtxA1 \[[@pone.0167699.ref003]\]. Polyphenols have also been reported to have antibacterial activity against many bacteria including *Vibrio* species \[[@pone.0167699.ref009]\]. The health-promoting effects of polyphenols are generally attributed to their antioxidant action \[[@pone.0167699.ref010]\]. A polyphenol pyrogallol (benzene-1,2,3-triol) has been shown to possess both anti- and pro-oxidant properties \[[@pone.0167699.ref011]\]. The prooxidant activity of pyrogallol (i.e., the ability to generate reactive oxygen species such as hydrogen peroxide) may be an important beneficial mechanism as an anti-infection drug \[[@pone.0167699.ref011]\]. Accordingly, the pharmacological activities of pyrogallol have been studied in infectious diseases; in particular, pyrogallol has been suggested to be a potential inhibitor of *Helicobacter pylori* urease and *Vibrio harveyi* quorum sensing \[[@pone.0167699.ref012]\]. In the present study, we investigated the effects of pyrogallol on the growth and cytotoxicity of *V*. *vulnificus*. In addition, we evaluated pyrogallol-induced toxicity in wild-type (wt) *V*. *vulnificus* and in a catalase-peroxidase (*katG*^*−*^) mutant strain.

Materials and Methods {#sec002}
=====================

Bacterial strains and reagents {#sec003}
------------------------------

*V*. *vulnificus* strains were grown in heart infusion (HI) broth (Difco, Becton-Dickinson, Bedford, MA, USA) in a shaking incubator at 200 rpm and 37°C. *V*. *vulnificus* MO6-24/O, a clinical isolate was provided by J. Glenn Morris, Jr., of the University of Maryland \[[@pone.0167699.ref013]\]. MO6-24/O has been used as a standard cytotoxic strain in *V*. *vulnificus* pathogenesis study and the complete genome sequence was annotated \[[@pone.0167699.ref014]\]. A catalase-peroxidase deletion mutant (*katG*^*−*^) was constructed in *V*. *vulnificus* wild type (wt) strain MO6-24/O using a counter-selection strategy and the suicide vector pKAS32 \[[@pone.0167699.ref015], [@pone.0167699.ref016]\]. Polymerase chain reaction (PCR) was used to confirm the internal deletion (172--1,793 base pair) within the *katG* gene composed of 2,172 nucleotides. Pyrogallol, catalase, and hydrogen peroxide (H~2~O~2~) (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in phosphate-buffered saline (PBS).

Cell culturing {#sec004}
--------------

HeLa cells (Korea Cell Line Bank, Seoul, Korea) were cultured in Dulbecco\'s Modified Eagle\'s Medium (DMEM; Welgene, Kyeongsan-si, Korea) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Carlsbad, CA, USA) at 37°C in an incubator with a 5% CO~2~ atmosphere.

Trypan blue staining of HeLa cells infected with *V*. *vulnificus* {#sec005}
------------------------------------------------------------------

HeLa cells were seeded in a 48-well cell culture plate (5×10^4^ cells/well) and cultured overnight. The cells were treated with serum-free DMEM plus pyrogallol (50 μg/mL) for 1 h prior to *V*. *vulnificus* infection at a multiplicity of infection (MOI) of 20 for 2 h. The HeLa cells were stained with a Trypan blue solution (Sigma-Aldrich) for 10 min, followed by washing with PBS. The Cell images were acquired using an inverted microscope with a digital camera (Nikon, Tokyo, Japan).

Measuring the effects of pyrogallol and H~2~O~2~ on *V*. *vulnificus*-induced HeLa cell cytotoxicity {#sec006}
----------------------------------------------------------------------------------------------------

*V*. *vulnificus* cytotoxicity in HeLa cells was measured using a CytoTox96 non-radioactive cytotoxicity assay kit (Promega, Madison, WI, USA) as previously described \[[@pone.0167699.ref003], [@pone.0167699.ref005]\]. HeLa cells were seeded in a 48-well cell culture plate (5 × 10^4^ cells/well) and cultured overnight. The cells were then washed with serum-free DMEM and treated with pyrogallol or H~2~O~2~ for 1 h prior to *V*. *vulnificus* infection at an MOI of 20 for 2h. Lactate dehydrogenase (LDH) released into the supernatant was assayed as a cytotoxicity marker in accordance with the manufacturer's protocol.

Determining the effects of pyrogallol and H~2~O~2~ on HeLa cell viability {#sec007}
-------------------------------------------------------------------------

HeLa cells cultured in 96-well microplates overnight were washed with serum-free DMEM and treated with pyrogallol (20--100 μg/mL) in a 37°C incubator with 5% CO~2~ for 24 h. Cell viability was measured using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, WI, USA) in accordance with the manufacturer's protocol.

HeLa cells were treated with H~2~O~2~ (0.25--1.0 mM) in a 37°C incubator with 5% CO~2~ for 2 h and cytotoxicity was measured using CytoTox96 as described above.

Measuring the effects of pyrogallol, catalase, and H~2~O~2~ on the growth of *V*. *vulnificus* {#sec008}
----------------------------------------------------------------------------------------------

*V*. *vulnificus* wild type or the *katG*^−^ mutant strains were grown in a shaking incubator at 37°C overnight and the culture suspensions were diluted 1:1000 into fresh HI broth. The diluted bacterial suspensions were inoculated into 96-well microplates with pyrogallol (20--100 μg/mL) or catalase (10 μg/mL) and then incubated at 37°C for 6 h. Bacterial growth was determined by measuring the absorbance at 600 nm using a SpectraMax 190 microplate reader (Molecular Devices, Sunnyvale, CA, USA). To assay bacterial growth in a shaking incubator for 24 h, the diluted suspensions of *V*. *vulnificus* were cultured in 50-mL tubes and the optical density was measured every 3 h using a Biophotometer (Eppendorf, Hamburg, Germany).

To test the effect of H~2~O~2~ (0.25--1.0 mM) on *V*. *vulnificus* viability, approximately 1 × 10^7^ colony forming units/mL (CFU/mL) of *V*. *vulnificus* wt or the *katG*^−^ mutant strains were cultured in DMEM for 2 h. For enumeration of live bacterial cells, the *V*. *vulnificus* culture suspensions were 10-fold serially diluted with PBS. The serial dilutions (10 μL) were loaded on HI agar plates and incubated in a 37°C incubator overnight.

Production of a polyclonal antibody against the KatG protein and Western blot analysis of *V*. *vulnificus* KatG and RtxA1 {#sec009}
--------------------------------------------------------------------------------------------------------------------------

A DNA fragment encoding the *V*. *vulnificus katG* gene was amplified by PCR using a DNA polymerase (TaKaRa, Tokyo, Japan) and cloned into the pGEX-4T expression vector (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA). The constructed plasmid was transformed into *E*. *coli* DH5α and the glutathione *S*-transferase (GST)-fusion protein was induced according to the manufacturer's protocol (Amersham Pharmacia Biotech). The resulting GST-KatG fusion protein was purified by affinity chromatography in accordance with the manufacturer\'s recommendations (Amersham Pharmacia Biotech). A polyclonal antibody against the GST-KatG fusion protein was produced using New Zealand white rabbits according to previously described methods \[[@pone.0167699.ref017]\].

*V*. *vulnificus* wt and the *katG*^*−*^ mutant strains were cultured in HI broth with or without pyrogallol (50 μg/mL) or catalase (10 μg/mL) in a 37°C shaking incubator for 6 h or 24 h. For KatG protein analysis, the bacterial pellets (2 × 10^8^ CFU) were suspended in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer and boiled in a water bath for 10 min. For RtxA1, 300 μL supernatants from bacteria cultured in HI for 6 h were concentrated using cold acetone. RtxA1 was detected using an anti-rabbit RtxA1 antibody specific to RtxA1-C \[[@pone.0167699.ref007]\]. Protein detection was conducted using the Western blotting Luminol reagent (Santa Cruz Biotechnology, Dallas, TX, USA) and a C300 chemiluminescence imager (Azure Biosystems, Inc., Dublin, CA, USA), according to a previously described method \[[@pone.0167699.ref007], [@pone.0167699.ref017]\]. Quantitative protein analysis and determination of fold increase in protein levels were performed by densitometric analysis using the ImageJ program (Azure Biosystems).

Statistical analysis {#sec010}
--------------------

Statistical differences were evaluated using one way ANOVA. All experiments were repeated three times and the results shown are from representative experiments. All results are presented as the means ± standard error of the mean (SEM).

Results {#sec011}
=======

Effect of pyrogallol on *V*. *vulnificus*-induced HeLa cell cytotoxicity {#sec012}
------------------------------------------------------------------------

Live *V*. *vulnificus* is highly toxic to host cells; this cytotoxicity is caused mainly by the RtxA1 toxin \[[@pone.0167699.ref005]\]. To identify compounds possessing inhibitory effects on *V*. *vulnificus* cytotoxicity, several natural products were tested using the Trypan blue staining method. Treatment with pyrogallol (50 μg/mL) prevented HeLa cells from becoming damaged by the pathogen ([Fig 1A](#pone.0167699.g001){ref-type="fig"}). Pyrogallol did not show any cytotoxicity to host cells ([Fig 1A](#pone.0167699.g001){ref-type="fig"}). The inhibitory effect of pyrogallol on *V*. *vulnificus* cytotoxicity was quantified using the LDH assay, which demonstrated that pyrogallol significantly inhibited the cytotoxicity ([Fig 1B](#pone.0167699.g001){ref-type="fig"}). The safety of pyrogallol in host cells was also tested using the MTS assay. Pyrogallol did not exhibit any cytotoxicity in HeLa cells ([Fig 1C](#pone.0167699.g001){ref-type="fig"}), which indicates that it has relatively low toxicity in human cells.

![Effect of pyrogallol on *Vibrio vulnificus*-induced cytotoxicity in HeLa cells.\
(A) HeLa cells pretreated with pyrogallol (50 μg/mL) for 1 h were infected with *V*. *vulnificus* at an MOI of 20 for 2 h. The cells were then stained with Trypan blue and the images were acquired using a microscope with a digital camera. (B) HeLa cells pretreated with pyrogallol (10--50 μg/mL) for 1 h were infected with *V*. *vulnificus* at an MOI of 20 for 2 h. LDH released into the supernatant was assayed as a cytotoxicity marker. (C) HeLa cells were cultured in a 96-well microplate with or without pyrogallol for 24 h and then incubated with MTS at 37°C for 4 h. All values are expressed as the means ± SEM (^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).](pone.0167699.g001){#pone.0167699.g001}

Effects of pyrogallol on *V*. *vulnificus* growth in HI broth {#sec013}
-------------------------------------------------------------

To investigate the effects of pyrogallol on *V*. *vulnificus* growth, bacterial suspensions cultured overnight were diluted 1,000-fold in HI broth and inoculated into 96-well microplates with or without pyrogallol. The plates were then incubated at 37°C for 6 h and bacterial growth was determined by measuring the absorbance at 600 nm. The results show that pyrogallol (20--100 μg/mL) significantly inhibited *V*. *vulnificus* growth in a dose-dependent manner ([Fig 2](#pone.0167699.g002){ref-type="fig"}). The minimum inhibitory concentration (MIC) of pyrogallol on *V*. *vulnificus* growth was approximately 37.6 μg/mL.

![Effects of pyrogallol on *Vibrio vulnificus* growth in HI broth.\
A *V*. *vulnificus* suspension cultured overnight in HI broth was diluted in 1,000-fold into a 96-well microplate with or without pyrogallol and cultured in a 37°C incubator for 6 h. Bacterial growth was determined by measuring the absorbance at 600 nm using a microplate reader. The data represent the means ± SEM of three experiments (^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).](pone.0167699.g002){#pone.0167699.g002}

Effects of pyrogallol and catalase on the growth of *V*. *vulnificus* wild type and the *katG*^*−*^ mutant strain {#sec014}
-----------------------------------------------------------------------------------------------------------------

To determine the inhibitory mechanism of pyrogallol, the growth of *V*. *vulnificus* wt and the *katG*^−^ mutant strain was compared in HI broth with or without pyrogallol. The effect of pyrogallol (50 μg/mL) on *V*. *vulnificus* growth was more significant during log phase (3--6 h) than in stationary phase ([Fig 3A](#pone.0167699.g003){ref-type="fig"}). In addition, the *katG* mutation itself resulted in a growth defect ([Fig 3B](#pone.0167699.g003){ref-type="fig"}). The growth inhibition effect of pyrogallol was more significant in the *katG*^−^ mutant strain than in the wild type strain ([Fig 3A and 3B](#pone.0167699.g003){ref-type="fig"}). The *katG*^−^ mutant strain did not exhibit any growth in the presence of pyrogallol (50 μg/mL) after 24 h, whereas the wild type strain showed growth recovery in stationary phase ([Fig 3C](#pone.0167699.g003){ref-type="fig"}). This growth inhibition due to pyrogallol was partly reversed by catalase treatment (10 μg/mL) ([Fig 3A--3C](#pone.0167699.g003){ref-type="fig"}).

![Effect of pyrogallol and catalase on the growth of wild-type (wt) *Vibrio vulnificus* and the *katG*^*−*^ mutant strain.\
*V*. *vulnificus* wt (A) and the *katG*^−^ mutant (B) cultured overnight in HI broth were diluted 1,000-fold into fresh HI broth with or without pyrogallol (50 μg/mL) or catalase (10 μg/mL). Bacterial growth was determined by measuring the absorbance at 600 nm using a Biophotometer. (C) *V*. *vulnificus* strains were cultured in HI broth with or without pyrogallol or catalase for 24 h and the culture suspensions were then 10-fold serially diluted with PBS. The serial dilutions (10 μL) were then loaded on HI agar plates and incubated at 37°C overnight (pyr: pyrogallol, cat: catalase).](pone.0167699.g003){#pone.0167699.g003}

Effect of H~2~O~2~ on *V*. *vulnificus* and HeLa cells {#sec015}
------------------------------------------------------

The effect of H~2~O~2~ was monitored on the viability of both bacteria and host cells in DMEM. Hydrogen peroxide decreased *V*. *vulnificus* growth ([Table 1](#pone.0167699.t001){ref-type="table"}) but did not show any cytotoxic effect on HeLa cells ([Fig 4A](#pone.0167699.g004){ref-type="fig"}). *V*. *vulnificus* cytotoxicity against HeLa cells decreased following H~2~O~2~ treatment ([Fig 4B](#pone.0167699.g004){ref-type="fig"}). The effects of H~2~O~2~ were more significant in the *katG*^−^ mutant than in wt *V*. *vulnificus*.

![Effect of hydrogen peroxide on *Vibrio vulnificus* growth and HeLa cell cytotoxicity.\
(A) HeLa cells were treated with H~2~O~2~ (0.25--1 mM) in DMEM for 150 min. (B) HeLa cells pretreated with H~2~O~2~ (0.25--1 mM) for 1 h were infected with *V*. *vulnificus* strains at an MOI of 20 for 150 min. LDH released into the supernatant was assayed as a cytotoxicity marker. All values are expressed as the means ± SEM (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).](pone.0167699.g004){#pone.0167699.g004}

10.1371/journal.pone.0167699.t001

###### Effect of hydrogen peroxide (H~2~O~2~) on *V*. *vulnificus* growth.

![](pone.0167699.t001){#pone.0167699.t001g}

  Strains            H~2~O~2~ (mM)                                                              
  ------------------ ---------------------- ------------------------ -------------------------- -------
  **wt (CFU)**       2.8×10^7^±0.46×10^7^   3.8×10^7^±0.31×10^7^\*   3.0×10^6^±0.12×10^6^\*     **0**
  ***katG¯*(CFU)**   2.4×10^7^±0.20×10^7^   3.6×10^6^±0.88×10^6^\*   6.0×10^6^±0.33×10^6^\*\*   **0**

*V*. *vulnificus* wt and the *katG*^−^ mutant strains were cultured in DMEM with or without H~2~O~2~ for 2 h. The culture suspensions were 10-fold serially diluted. Each dilutions (10 μL) was plated on HI agar plates and incubated at 37°C overnight. Colony numbers were analyzed as viable bacterial numbers. All values are expressed as the means ± SEM (^\*^*p* \< 0.05; ^\*\*^*p* \<0.01).

Effect of pyrogallol and catalase on KatG expression in *V*. *vulnificus* {#sec016}
-------------------------------------------------------------------------

To study the role of KatG in the effect of the prooxidant pyrogallol, Western blot analysis was performed using *V*. *vulnificus* cells. At 6 h of incubation, pyrogallol significantly increased the expression of KatG in *V*. *vulnificus* wt ([Fig 5A](#pone.0167699.g005){ref-type="fig"}). In contrast, catalase decreased pyrogallol-induced KatG expression ([Fig 5A](#pone.0167699.g005){ref-type="fig"}). In addition, KatG expression was higher in a 24 h culture (stationary phase) than in a 6 h culture (log phase) ([Fig 5B](#pone.0167699.g005){ref-type="fig"}).

![Effect of pyrogallol on the expression of KatG and RtxA1 proteins in *Vibrio vulnificus*.\
(A) *V*. *vulnificus* wt or *katG*^*−*^ mutant strains were cultured in HI broth with pyrogallol (50 μg/mL) or catalase (10 μg/mL) in a 37°C shaking incubator for 6 h. The bacterial pellets (2 × 10^8^ CFU) were used for KatG protein detection by Western blot analysis. (B) Western blot analysis of KatG in *V*. *vulnificus* bacterial pellets (2 × 10^8^ CFU) cultured for 6 h or 24 h. (C) Western blot analysis of RtxA1 toxin in the supernatants of *V*. *vulnificus* cultured in HI broth for 6 h (pyr: pyrogallol, cat: catalase). (C) *V*. *vulnificus* strains were cultured in HI broth for 6 h. The proteins in culture supernatants (300μl) were precipitated using cold acetone and RtxA1 protein was detected by Western blotting.](pone.0167699.g005){#pone.0167699.g005}

Effect of pyrogallol and catalase on RtxA1 expression in *V*. *vulnificus* {#sec017}
--------------------------------------------------------------------------

The RtxA1 toxin, a major cytotoxin of *V*. *vulnificus* was detected in culture supernatants of *V*. *vulnificus* grown in HI broth with pyrogallol or catalase for 6 h. RtxA1 protein was not detected in the HI culture with pyrogallol, which was restored by the addition of catalase ([Fig 5C](#pone.0167699.g005){ref-type="fig"}).

Discussion {#sec018}
==========

*V*. *vulnificus*, a serious opportunistic human pathogen, causes rapidly progressing, fatal septicemia, resulting in a mortality rate of \> 50% within a few days of infection. Several recent reports have shown that the incidence of human *Vibrio* illnesses is increasing worldwide; this may be associated with the global warming phenomenon and a rise in sea surface temperatures \[[@pone.0167699.ref018]\]. In addition, numerous *V*. *vulnificus* isolates have been shown to be resistant to antibiotics routinely prescribed for treating infections caused by this pathogen \[[@pone.0167699.ref019], [@pone.0167699.ref020]\]. Therefore, we have attempted to identify new compounds from natural products with therapeutic activity against *V*. *vulnificus* \[[@pone.0167699.ref003]\]. The results of the present study show that pyrogallol significantly inhibits the growth of *V*. *vulnificus* and decreases the pathogen-induced cytotoxicity in HeLa cells ([Fig 1](#pone.0167699.g001){ref-type="fig"} and [Fig 2](#pone.0167699.g002){ref-type="fig"}). Importantly, pyrogallol did not exhibit any toxicity in the host cells, based on cell morphology and viability ([Fig 1A and 1C](#pone.0167699.g001){ref-type="fig"}).

Pyrogallol has been reported to possess both antioxidant and prooxidant properties \[[@pone.0167699.ref011]\]. In support of this functionality, a mutant strain defective in an oxidative stress-related protein (*katG*^*−*^) did not show any growth in the presence of pyrogallol ([Fig 3B](#pone.0167699.g003){ref-type="fig"}). The KatG protein has been reported to be significantly upregulated during the resuscitation of viable but nonculturable *V*. *vulnificus* cells \[[@pone.0167699.ref021]\]. Here, we confirmed that KatG expression increased in *V*. *vulnificus* during stationary phase ([Fig 5B](#pone.0167699.g005){ref-type="fig"}) and in a culture incubated with pyrogallol ([Fig 4A](#pone.0167699.g004){ref-type="fig"}). Additionally, the growth inhibition caused by pyrogallol could be partly reversed by co-treatment with exogenous catalase in both *V*. *vulnificus* wt and the *katG*^*−*^ mutant strain ([Fig 3](#pone.0167699.g003){ref-type="fig"}). In particular, the prooxidant ability of pyrogallol to generate reactive oxygen species such as H~2~O~2~ has been suggested as an important beneficial mechanism. Our results show that H~2~O~2~ exhibits inhibitory effects on *V*. *vulnificus* growth ([Table 1](#pone.0167699.t001){ref-type="table"}) similar to those mediated by pyrogallol. Catalase partly reduced the effects of pyrogallol ([Fig 3](#pone.0167699.g003){ref-type="fig"}). These results indicate that pyrogallol might inhibit *V*. *vulnificus* growth via the production of reactive oxygen species. The growth inhibition in HI broth culture by pyrogallol was more significant in log phase than in stationary phase ([Fig 3](#pone.0167699.g003){ref-type="fig"}). Pyrogallol also caused the decrease of RtxA1 expression in HI broth culture for 6 h ([Fig 5C](#pone.0167699.g005){ref-type="fig"}), which might result from the growth inhibition.
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